Ermira Pazolli, Ph.D.
Affiliations: | 2010 | Biology & Biomedical Sciences (Molecular Cell Biology) | Washington University, Saint Louis, St. Louis, MO |
Area:
Cell BiologyGoogle:
"Ermira Pazolli"Parents
Sign in to add mentor| Sheila A. Stewart | grad student | 2010 | Washington University | |
| (The function and regulation of senescent stromal-derived OPN.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Aird D, Teng T, Huang CL, et al. (2019) Sensitivity to splicing modulation of BCL2 family genes defines cancer therapeutic strategies for splicing modulators. Nature Communications. 10: 137 |
| Aird D, Teng T, Huang C, et al. (2019) Abstract 281: Sensitivity to splicing modulation of BCL2 family genes reveals cancer therapeutic strategies for splicing modulators Cancer Research. 79: 281-281 |
| Seiler M, Yoshimi A, Darman R, et al. (2018) H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers. Nature Medicine |
| Flanagan KC, Alspach E, Pazolli E, et al. (2018) c-Myb and C/EBPβ regulate OPN and other senescence-associated secretory phenotype factors. Oncotarget. 9: 21-36 |
| Buonamici S, Yoshimi A, Thomas M, et al. (2017) Abstract 1185: H3B-8800, a novel orally available SF3b modulator, shows preclinical efficacy across spliceosome mutant cancers Cancer Research. 77: 1185-1185 |
| Weir HM, Bradbury RH, Lawson M, et al. (2016) AZD9496: An oral estrogen receptor inhibitor that blocks the growth of ER-positive and ESR1 mutant breast tumours in preclinical models. Cancer Research |
| Buonamici S, Yoshimi A, Thomas M, et al. (2016) H3B-8800, an Orally Bioavailable Modulator of the SF3b Complex, Shows Efficacy in Spliceosome-Mutant Myeloid Malignancies Blood. 128: 966-966 |
| Buonamici S, Darman R, Perino S, et al. (2015) Heterozygous Hotspot SF3B1 Mutations Found in Myelodysplastic Syndromes Downregulate Genes Involved in Differentiation of Erythroid Cells Blood. 126: 1643-1643 |
| Park ES, Aicher M, Aird D, et al. (2015) Abstract 2941: Targeting MCL1-dependent cancers through RNA splicing modulation Cancer Research. 75: 2941-2941 |
| Aird D, Pazolli E, Furman C, et al. (2015) Abstract C8: Targeting MCL1-dependent cancers with SF3B splicing modulators Molecular Cancer Therapeutics. 14 |